Publications by authors named "Francisco F Lopez"

The pathotropic targeting of therapeutic nanoparticles to cancerous lesions is an innovative concept that has recently been reduced to practice in clinical trials for the treatment of metastatic cancer. Previously, we reported that intravenous infusions of Rexin-G, a pathotropic nanoparticle (or vector) bearing a cyto-ablative construct, induced tumor regression, reduced tumor burden, and improved survival, while enhancing the overall quality-of-life of patients with otherwise intractable chemotherapy-resistant cancers. In this report, we describe the major histopathological and radiologic features that are characteristic of solid tumors under the destructive influences of Rexin-G administered as a single therapeutic agent.

View Article and Find Full Text PDF

Metastatic cancer is a life-threatening illness with a predictably fatal outcome, thereby representing a major unmet medical need. In 2003, Rexin-G became the world's first targeted injectable vector approved for clinical trials in the treatment of intractable metastatic disease. Uniquely suited, by design, to function within the context of the human circulatory system, Rexin-G is a pathotropic (disease-seeking) gene delivery system bearing a designer killer gene; in essence, a targeted nanoparticle that seeks out and selectively accumulates in metastatic sites upon intravenous infusion.

View Article and Find Full Text PDF

Concentrations of aluminium in drinking waters (tap water, still mineral water and sparkling mineral water), fruit juices and soft drinks were determined using graphite furnace atomic absorption spectrometry (GFAAS) of samples processed with a HNO3-V205 acid digestion pre-treatment. In water samples, aluminium was determined directly. We verified the sensitivity, accuracy and precision of the method and ruled out matrix interferences.

View Article and Find Full Text PDF